J. Goldman & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

J. Goldman & Co’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-27,100	Closed	-$497K	–	464
2024 Q4	$497K	Buy	+27,100	New	+$437K	0.01%	364
2023 Q3	–	Sell	-27,000	Closed	-$647K	–	353
2023 Q2	$647K	Sell	27,000 -13,500	-33%	-$300K	0.02%	276
2023 Q1	$762K	Buy	+40,500	New	+$771K	0.03%	245
2022 Q3	–	Sell	-27,000	Closed	-$381K	–	379
2022 Q2	$381K	Buy	27,000 +12,000	+80%	+$224K	0.02%	296
2022 Q1	$363K	Buy	+15,000	New	+$363K	0.02%	302
2018 Q3	–	Sell	-65,000	Closed	-$993K	–	254
2018 Q2	$993K	Buy	+65,000	New	+$1.16M	0.05%	257

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

J. Goldman & Co's ACAD Position: Q3 2025 in Review

J. Goldman & Co sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 164,278 shares — an estimated $3.89M sold.

J. Goldman & Co first reported a position in ACAD in Q2 2018 and held it in 4 quarters. The position peaked at $3.54M in Q2 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

J. Goldman & Co reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
J. Goldman & Co sold 164,278 Acadia Pharmaceuticals shares in Q3 2025, an estimated $3.89M.
J. Goldman & Co first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 4 quarters.
J. Goldman & Co's Acadia Pharmaceuticals position peaked at $3.54M in Q2 2025.
334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.